IL204143A - A cancer treatment kit containing the respective pharmaceutical compositions containing: - Google Patents

A cancer treatment kit containing the respective pharmaceutical compositions containing:

Info

Publication number
IL204143A
IL204143A IL204143A IL20414310A IL204143A IL 204143 A IL204143 A IL 204143A IL 204143 A IL204143 A IL 204143A IL 20414310 A IL20414310 A IL 20414310A IL 204143 A IL204143 A IL 204143A
Authority
IL
Israel
Prior art keywords
cancer
agent
kit
pharmaceutical composition
respectively comprises
Prior art date
Application number
IL204143A
Other languages
English (en)
Hebrew (he)
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of IL204143A publication Critical patent/IL204143A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL204143A 2007-08-24 2010-02-24 A cancer treatment kit containing the respective pharmaceutical compositions containing: IL204143A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95792307P 2007-08-24 2007-08-24
PCT/JP2008/002232 WO2009028150A1 (en) 2007-08-24 2008-08-19 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
IL204143A true IL204143A (en) 2013-04-30

Family

ID=40386893

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204143A IL204143A (en) 2007-08-24 2010-02-24 A cancer treatment kit containing the respective pharmaceutical compositions containing:

Country Status (19)

Country Link
US (1) US8703713B2 (OSRAM)
EP (1) EP2195003A4 (OSRAM)
JP (1) JP5417667B2 (OSRAM)
KR (1) KR20100047899A (OSRAM)
CN (1) CN101883577A (OSRAM)
AR (1) AR068020A1 (OSRAM)
AU (1) AU2008292966C1 (OSRAM)
BR (1) BRPI0815726A2 (OSRAM)
CA (1) CA2697501A1 (OSRAM)
IL (1) IL204143A (OSRAM)
MX (1) MX2010002178A (OSRAM)
MY (1) MY160406A (OSRAM)
NZ (1) NZ583578A (OSRAM)
RU (1) RU2472522C2 (OSRAM)
SG (1) SG183770A1 (OSRAM)
TW (1) TWI436775B (OSRAM)
UA (1) UA100702C2 (OSRAM)
WO (1) WO2009028150A1 (OSRAM)
ZA (1) ZA201001580B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073620B (zh) 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US20080034017A1 (en) * 2006-08-04 2008-02-07 Dominic Giampaolo Links to a common item in a data structure
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
EP2578233B1 (en) * 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
DE102013214023B4 (de) * 2013-07-17 2015-02-12 Siemens Aktiengesellschaft Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist
PL3597742T3 (pl) * 2014-10-09 2022-11-14 Yamaguchi University Wektor ekspresyjny CAR oraz komórki T wykazujące ekspresję CAR
KR102478073B1 (ko) * 2014-10-14 2022-12-16 립타이드 바이오사이언스, 인코포레이티드 항-염증 특성을 갖는 펩타이드
JP7168228B2 (ja) * 2017-05-19 2022-11-09 慶應義塾 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB213645A (en) 1922-12-22 1924-03-24 Frank Lincoln Morse Improvements in and relating to chain and sprocket wheel gearing
US3265572A (en) * 1961-09-20 1966-08-09 S B Penick And Company Process for preparing tyrociding and product produced thereby
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1994021679A1 (en) * 1993-03-25 1994-09-29 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
WO1999040118A1 (en) 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
WO1999059636A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
CN103073620B (zh) * 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
WO2005117887A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
US7691827B2 (en) 2004-12-17 2010-04-06 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2008099908A1 (ja) 2007-02-16 2008-08-21 Oncotherapy Science, Inc. 脈絡膜新生血管のワクチン療法

Also Published As

Publication number Publication date
AU2008292966A1 (en) 2009-03-05
MX2010002178A (es) 2010-03-18
EP2195003A1 (en) 2010-06-16
RU2010111139A (ru) 2011-09-27
CA2697501A1 (en) 2009-03-05
JP5417667B2 (ja) 2014-02-19
CN101883577A (zh) 2010-11-10
TWI436775B (zh) 2014-05-11
JP2010536714A (ja) 2010-12-02
AU2008292966C1 (en) 2013-03-14
NZ583578A (en) 2012-07-27
AU2008292966B2 (en) 2012-07-19
BRPI0815726A2 (pt) 2016-01-05
SG183770A1 (en) 2012-09-27
AR068020A1 (es) 2009-10-28
ZA201001580B (en) 2011-02-23
EP2195003A4 (en) 2011-07-06
TW200914037A (en) 2009-04-01
US20110082088A1 (en) 2011-04-07
WO2009028150A1 (en) 2009-03-05
US8703713B2 (en) 2014-04-22
KR20100047899A (ko) 2010-05-10
RU2472522C2 (ru) 2013-01-20
UA100702C2 (ru) 2013-01-25
MY160406A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
IL204143A (en) A cancer treatment kit containing the respective pharmaceutical compositions containing:
IL208451A0 (en) Pharmaceutical compositions comprising a chemotherapeutic agent and an anti-glypican 3 antibody for use in treating hepatic cancer
PT2601962T (pt) Regime de dosagem de lag-3 para utilização no tratamento de cancro
IL194429A0 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
IL201065A (en) History of benzyl glycoside and pharmacological preparations containing them for the treatment of diabetes
IL186535A0 (en) Pharmaceutical compositions for elimination of heterogeneous and mixed cell populations in tumors
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
IL193240A0 (en) Dihydrodiazepine derivatives and pharmaceutical compositions containing the same
IL178775A0 (en) Pharmaceutical compositions for acute glucocorticoid therapy
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
IL182020A0 (en) Pharmaceutical composition comprising diclofenac
ZA200803758B (en) Oxazole compound and pharmaceutical composition
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL195861A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
EP1749095A4 (en) NEW THERAPEUTIC TARGETS IN CANCER
PL2120864T3 (pl) Kompozycja do podawania składników biologicznie czynnych w okolicy narządów płciowych i odbytnicy, i jej zastosowania
IL203898A0 (en) Cdca1 peptide and pharmaceutical agent comprising the same
IL194678A (en) Kinase inhibitors, pharmaceutical preparations containing them and their uses in the preparation of a drug for the treatment of cancer in mammals
IL197107A0 (en) Pharmaceutical compositions including vitamin d and corticosteriod
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
EP2005954B8 (en) Kit for cancer therapy and pharmaceutical composition for cancer therapy
PL2046830T3 (pl) Polipeptydy CSF3R i ich zastosowania
EP1809291A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL LEVY
PT1803456E (pt) Composições farmacêuticas que compreendem l-733060 para utilização no tratamento de tumores cancerígenos
GB0625100D0 (en) Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees